{"id":"W4212951999","doi":"10.1200/jco.2022.40.6_suppl.304","title":"Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; University of Ottawa; McGill University Health Centre; Université Laval; Centre Hospitalier de l’Université de Montréal; Dalhousie University; Health Sciences Centre; Ottawa Hospital; University Health Network; University of British Columbia; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary; Princess Margaret Cancer Centre; Hôtel-Dieu de Québec; BC Cancer Agency; McMaster University","funders":"","keywords":"Medicine; Pazopanib; Temsirolimus; Sunitinib; Axitinib; Nivolumab; Everolimus; Internal medicine; Pembrolizumab; Discontinuation; Renal cell carcinoma; Oncology; Ipilimumab; Sorafenib; Clinical endpoint; Clinical trial; Cancer; PI3K/AKT/mTOR pathway; Immunotherapy; Hepatocellular carcinoma; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001190271,0.0001860692,0.0006242201,0.0006677318,0.0003449444,0.0006973469,0.0004657063,0.0003995799,0.001285839],"category_scores_gemma":[0.003200181,0.0001031767,0.000787768,0.00088886,0.0002071676,0.0003689846,0.0002758324,0.0004687738,0.000112377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002832433,"about_ca_system_score_gemma":0.002519695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02784736,"about_ca_topic_score_gemma":0.07280708,"domain_scores_codex":[0.9992144,0.0001786516,0.00007835655,0.0001697503,0.000246731,0.0001120748],"domain_scores_gemma":[0.9975219,0.0007410899,0.001127677,0.00008070869,0.0001789489,0.0003495688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002491173,0.0001863339,0.9758598,0.0002333374,0.0004070955,0.00006978439,0.00003907895,0.0006357508,0.0002323009,0.00003216914,0.000978015,0.01883519],"study_design_scores_gemma":[0.0001999284,0.001156209,0.9956061,0.00004803566,0.0002967923,0.0003438141,0.00005678502,0.001054127,0.0001834521,0.00003692345,0.001009581,0.000008346932],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879957,0.006725036,0.00009055692,0.0002180077,0.00002093285,0.0000718721,0.003786352,0.00001388718,0.001077708],"genre_scores_gemma":[0.9958331,0.0006293617,0.0001425771,0.0001114002,0.00002369512,0.0000250497,0.003100665,0.000001939463,0.0001322349],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02784736,"threshold_uncertainty_score":0.05537051,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04208986358964661,"score_gpt":0.3673168581867393,"score_spread":0.3252269945970926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}